Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided.

Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided.

The present invention relates to an improved process for purification of bacterial capsular polysaccharides, more specifically capsular polysaccharides of gram negative bacteria. The process comprises of concentration and dia filtration of harvest, treatment with anionic detergent and strong alkali followed by centrifugation, diafiltration and cationic detergent based precipitation of bacterial polysaccharides. The process results in significant reduction of endotoxin, protein and nucleic acid impurities thereby providing higher recovery of capsular polysaccharide with the desired O-acetyl levels. Said process is scalable, non-enzymatic, and employs fewer purification steps.

The present invention discloses a preparation method of Cryptococcus neoformans capsular polysaccharide GXM as well as a GXM antigen immunoassay kit and an application thereof. The preparation method of the Cryptococcus neoformans capsular polysaccharide GXM effectively avoids the use of a toxic chemical reagent, ensures safety of operators, and also avoids environmental pollution, has high specificity, and can prepare a high-purity Cryptococcus neoformans capsular polysaccharide while simplifying a preparation process. The GXM antigen immunoassay kit adopts a competition method, has good sensitivity, specificity, repeatability and stability, has high recovery rate of a target compound and may provide more accurate and reliable inspection results. The kit is simple and feasible in use and operation, rapid and sensitive in detection and low in price and provides an effective tool for clinical detection of GXM.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.